Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Total Current Liabilities (2016 - 2026)

Myriad Genetics has reported Total Current Liabilities over the past 16 years, most recently at $133.8 million for Q4 2025.

  • Quarterly Total Current Liabilities fell 18.46% to $133.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $133.8 million through Dec 2025, down 18.46% year-over-year, with the annual reading at $133.8 million for FY2025, 18.46% down from the prior year.
  • Total Current Liabilities was $133.8 million for Q4 2025 at Myriad Genetics, down from $148.0 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $271.0 million in Q2 2021 and troughed at $119.7 million in Q2 2022.
  • The 5-year median for Total Current Liabilities is $152.7 million (2024), against an average of $167.8 million.
  • Year-over-year, Total Current Liabilities crashed 55.83% in 2022 and then surged 84.71% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $204.3 million in 2021, then tumbled by 32.84% to $137.2 million in 2022, then grew by 13.63% to $155.9 million in 2023, then rose by 5.26% to $164.1 million in 2024, then dropped by 18.46% to $133.8 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Total Current Liabilities are $133.8 million (Q4 2025), $148.0 million (Q3 2025), and $199.9 million (Q2 2025).